SCHEMBL4015262

SCHEMBL4015262

Nc1ccc2cn(-c3nccc(Nc4ccc(Cl)cc4)n3)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 7/20 0.44
KCNH2 Q12809 2/20 0.44
SCN5A Q14524 1/20 0.44
ROCK1 Q13464 2/20 0.38
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
HTR3A P46098 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
NSD2 O96028 1/20 0.38
ALDH1A1 P00352 1/20 0.38
KDR P35968 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
ROCK2 O75116 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4415303 0.82 AURKA (0.42) SCN9AKDM4EMAPTALDH1A1KDR
SCHEMBL4013574 0.82 MEN1 (0.48) SCN9AKCNH2ROCK1MAPTALDH1A1
SCHEMBL4428333 0.75 PTGES (0.43) SCN9AKDM4EMAPTALDH1A1KDR
SCHEMBL4014022 0.75 ROCK1 (0.46) SCN9AKCNH2ROCK1MAPTALDH1A1
SCHEMBL3226759 0.73 NPC1 (0.55) KCNH2KDM4EMAPTNSD2ALDH1A1
SCHEMBL4416090 0.69 BCL6 (0.41) KDM4EMAPTALDH1A1KDRNPC1
SCHEMBL4210667 0.69 BCL6 (0.64) MAPTBCL6
SCHEMBL31337029 0.68 SCN9A (0.82) SCN9AKCNH2SCN5AROCK1HTR3E
SCHEMBL4012848 0.68 NPC1 (0.50) KDM4EMAPTNPC1RAB9ACYP1A2
SCHEMBL4014143 0.67 ACHE (0.55) KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US claimed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US claimed
US-8222262-B2 Indazolyl derivatives useful as potassium channel modulating agents NEUROSEARCH A/S (DK) 2012-07-17 US disclosed
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2009-12-31 US disclosed
EP-2074113-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NeuroSearch A/S (DK) 2009-07-01 EP disclosed
WO-2008040753-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2008-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325989-A1 INDAZOLYL DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS KCND2, KCNN3, KCNJ2 SCN9A 202/4885KCNH2 10/4885SCN5A 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.